Augusta University Research Inc — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$104,195	1
2024	Research	$7,875	4
2023	Research	$8,394	1
2020	Research	$264,343	1
2019	Research	$285,419	6

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $662,351 9 payments
Amylyx Pharmaceuticals, Inc. $7,875 4 payments

Studies the money was for Research payments · program years 2019–2025

A phase Ib ,II trial of pembrolizumab and idelalisib in patients with non-small cell lung cancer NSCLC $264,343 1 payment
A phase I,II trial of pembrolizumab and poly ICLC in patients with recurrent metastatic mismatch repair-proficient MRP colon cancer $188,776 1 payment
A phase I/II trial of pembrolizumab (MK-3475) and poly-ICLC in patients with metastatic mismatch repair-proficient (MRP) colon cancer $104,195 1 payment
A phase I,II trial of pembrolizumab and poly ICLC in patients with recurrent metastatic mismatch repair-proficient MRP colon cancer $50,336 1 payment
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Subjects with Advanced Endometrial Cancer $46,307 4 payments
# A phase I,II trial of pembrolizumab and poly ICLC in patients with recurrent metastatic mismatch repair-proficient MRP colon cancer $8,394 1 payment
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Amx0035 Versus Placebo for 48-Week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (Als) $7,875 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.